Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.49 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800123 | 1.00 | NPFFR1 (0.49) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL4800117 | 1.00 | NPFFR1 (0.49) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL8997535 | 0.82 | NPFFR2 (0.45) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL8997541 | 0.82 | NPFFR2 (0.45) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL4802326 | 0.79 | KDR (0.44) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL4802319 | 0.79 | KDR (0.44) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL2907979 | 0.79 | KDR (0.44) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL1462597 | 0.78 | ADRB2 (0.37) | NPFFR1NPFFR2KDRPDK1 | |
| SCHEMBL1462595 | 0.78 | ADRB2 (0.37) | NPFFR1NPFFR2KDRPDK1 | |
| SCHEMBL1462598 | 0.78 | ADRB2 (0.37) | NPFFR1NPFFR2KDRPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737842-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | NPFFR1 127/4885NPFFR2 165/4885KDR 1113/4885 |
| US-20050282857-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | NPFFR1 127/4885NPFFR2 165/4885KDR 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.